New combo attack on rare bone cancer tests safety
NCT ID NCT02989636
Summary
This early-phase study is checking the safety of combining an immunotherapy drug (nivolumab) with a very precise, high-dose radiation treatment for patients whose chordoma has come back or spread. It will enroll about 21 people to see how well they tolerate the treatments and to get early signs of whether the combination helps control the cancer. The main goal is to identify any serious side effects before testing if the approach works better than standard care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHORDOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.